TS 23

Drug Profile

TS 23

Alternative Names: DS-9231; TS23

Latest Information Update: 15 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Translational Sciences
  • Developer Daiichi Sankyo Company
  • Class Antithrombotics
  • Mechanism of Action Antiplasmin inhibitors; Fibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis

Most Recent Events

  • 07 Aug 2017 Phase-II clinical trials in Thrombosis in Hungary (IV) (EudraCT2017-000552-25)
  • 17 Sep 2015 Translational Sciences plans a phase II trial for Thrombosis (acute thrombotic vascular disorder) (Translational Biosciences website, September 2015)
  • 15 Sep 2015 TS 23 licensed to Daiichi Sankyo worldwide for the treatment and prevention of Thrombosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top